172 related articles for article (PubMed ID: 15675409)
21. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
22. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
23. Duloxetine: mechanism of action at the lower urinary tract and Onuf's nucleus.
Jost W; Marsalek P
Clin Auton Res; 2004 Aug; 14(4):220-7. PubMed ID: 15316838
[TBL] [Abstract][Full Text] [Related]
24. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
Wernicke JF; Pritchett YL; D'Souza DN; Waninger A; Tran P; Iyengar S; Raskin J
Neurology; 2006 Oct; 67(8):1411-20. PubMed ID: 17060567
[TBL] [Abstract][Full Text] [Related]
25. Bleeding gums: duloxetine may be the cause.
Balhara Y; Sagar R; Varghese ST
J Postgrad Med; 2007; 53(1):44-5. PubMed ID: 17244971
[TBL] [Abstract][Full Text] [Related]
26. Reboxetine: a norepinephrine selective reuptake pump inhibitor.
Preskorn SH
J Psychiatr Pract; 2004 Jan; 10(1):57-63. PubMed ID: 15334987
[No Abstract] [Full Text] [Related]
27. Burning paresthesia related to duloxetine therapy.
Woo YS; Bahk WM
J Clin Psychopharmacol; 2014 Jun; 34(3):392-4. PubMed ID: 24633002
[No Abstract] [Full Text] [Related]
28. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects.
Turcotte JE; Debonnel G; de Montigny C; Hébert C; Blier P
Neuropsychopharmacology; 2001 May; 24(5):511-21. PubMed ID: 11282251
[TBL] [Abstract][Full Text] [Related]
29. Digging for data on harms in duloxetine trials.
Doshi P; Zito J; dosReis S
BMJ; 2014 Jun; 348():g3578. PubMed ID: 24904123
[No Abstract] [Full Text] [Related]
30. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
31. [Successful phase III study with serotonin-noradrenaline reuptake inhibitor. Soon a drug to control stress incontinence].
MMW Fortschr Med; 2004 Feb; 146(7):59. PubMed ID: 15347056
[No Abstract] [Full Text] [Related]
32. [Stress incontinence in general practice].
Krankenpfl J; 2004; 42(7-10):228-9. PubMed ID: 15675390
[No Abstract] [Full Text] [Related]
33. Successful duloxetine treatment of a binge eating disorder: a case report.
Bernardi S; Pallanti S
J Psychopharmacol; 2010 Aug; 24(8):1269-72. PubMed ID: 19010975
[TBL] [Abstract][Full Text] [Related]
34. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.
Raskin J; Wang F; Pritchett YL; Goldstein DJ
Pain Med; 2006; 7(5):373-85. PubMed ID: 17014595
[TBL] [Abstract][Full Text] [Related]
35. Duloxetine: a review of its pharmacology and use in chronic pain management.
Bellingham GA; Peng PW
Reg Anesth Pain Med; 2010; 35(3):294-303. PubMed ID: 20921842
[TBL] [Abstract][Full Text] [Related]
36. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence.
Castro-Diaz D; Palma PC; Bouchard C; Haab F; Hampel C; Carone R; Zepeda Contreras S; Rodriguez Ginorio H; Voss S; Yalcin I; Bump RC;
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Aug; 18(8):919-29. PubMed ID: 17160693
[TBL] [Abstract][Full Text] [Related]
37. Coadministration of low-dose serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine with α 2-adrenoceptor blockers to treat both female and male mild-to-moderate stress urinary incontinence (SUI).
Alberti C
G Chir; 2013; 34(7-8):189-94. PubMed ID: 24091172
[TBL] [Abstract][Full Text] [Related]
38. Safety and adverse event profile of duloxetine.
Wernicke JF; Gahimer J; Yalcin I; Wulster-Radcliffe M; Viktrup L
Expert Opin Drug Saf; 2005 Nov; 4(6):987-93. PubMed ID: 16255658
[TBL] [Abstract][Full Text] [Related]
39. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
Clayton A; Kornstein S; Prakash A; Mallinckrodt C; Wohlreich M
J Sex Med; 2007 Jul; 4(4 Pt 1):917-29. PubMed ID: 17627739
[TBL] [Abstract][Full Text] [Related]
40. Duloxetine for management of stress urinary incontinence.
Guay DR
Am J Geriatr Pharmacother; 2005 Mar; 3(1):25-38. PubMed ID: 16089245
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
